Miglustat HCl (N-Butyldeoxynojirimycin) (OOMC00044)

Catalog No: OOMC00044

Product Info

• Product Format: Powder
• Additional Information: CAS: 210110-90-0
  Molecular Formula: C10H21NO4 HCl
  Chemical Name: N-Butyldeoxynojirimycin HCl
  Primary Activity: a-glucosidase, glycosyltransferase inhibitor
  COVID-19 Rationale: Inhibits galactosidase alpha (GLA), which interacts with SARS-CoV-2 Nsp14; analog of IHVR-19029, and antiviral in clinical trials
• Reconstitution and Storage: Soluble in DMSO (up to 20 mg/ml) or in Water (up to 20 mg/ml). Store at -20C.
• Purity: > 98%
• Reference: 1) Platt et al. (1994), N-butyldeoxynojirimycin is a novel inhibitor if glycolipid biosynthesis; J. Biol. Chem., 269 8362 2) Noel et al. (2008), Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis; J. Pharmacol. Exp. Ther., 325 1016 3) Abian et al. (2011), Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase; Mol. Pharm., 8 2390 4) Serratrice et al. (2015), Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series; J. Med. Case Rep., 9 146 5) Karimzadeh (2013), Effects of miglustat on stabilization of neurological disorder in niemann-pick disease type C: Iranian pediatric case series; J. Child Neurol., 28 1599

Target Info

• Alias Symbols: NB-DNJ
• Molecular Weight: 255.74 g/mol